UK markets open in 6 hours 8 minutes

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.35+0.58 (+10.05%)
At close: 04:00PM EST
6.40 +0.05 (+0.79%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.77
Bid6.35 x 3200
Ask6.36 x 900
Day's range5.93 - 6.39
52-week range4.86 - 24.90
Avg. volume3,693,309
Market cap796.9M
Beta (5Y monthly)0.34
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date09 Nov 2012
1y target estN/A
  • Motley Fool

    Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today

    Shares of the COVID-19 vaccine makers Pfizer (NYSE: PFE), Ocugen (NASDAQ: OCGN), and Vaxart (NASDAQ: VXRT) are all moving in the wrong direction today. Specifically, Pfizer's stock is down by approximately 4%, Ocugen's equity is in the red by 5.64%, and Vaxart's shares are underwater by a hefty 8.7%, as of 12:23 p.m. ET Monday afternoon. On Sunday, the White House's chief medical advisor, Dr. Anthony Fauci, said that the preliminary data regarding the severity of the omicron variant was "encouraging."

  • Motley Fool

    3 Vaccine Latecomers That Could Double Your Money

    Experts predict the coronavirus will stick around -- so a potential end to the pandemic wouldn't necessarily equal an end to the need for vaccination. In fact, you may see bigger returns from an investment in a smaller biotech company that hasn't yet reached the vaccine finish line. Positive clinical trial reports or regulatory submissions could be major catalysts.

  • Motley Fool

    3 COVID Pill Stocks That Might Be Game-Changers

    Despite the tremendous success of vaccines against the coronavirus, there's always more work to be done when it comes to reducing the risks associated with infection. If coronavirus vaccine development was the story of 2020, antiviral pill development might well be the story of 2021 and 2022. Pfizer (NYSE: PFE) is currently working on an antiviral pill for COVID-19 to add to its profitable coronavirus portfolio, where its highly successful vaccine is front and center.